



Provider Notice 14-34

Dear Provider,

Washington Apple Health (Medicaid), administered by the Health Care Authority (agency), will implement the following changes to the State Maximum Allowable Costs (SMAC) list for the fee-for-service (FFS) Prescription Drug Program:

MAC Adjustments			
Generic Name	Strength	Form	MAC Effective 07/01/14
ALENDRONATE SODIUM	70MG	TABLET	\$.76250
LEVETIRACETAM	500MG	TABLET	\$.14576
LITHIUM CARBONATE	300MG	TABLET CR	\$.21130
LOVASTATIN	10MG	TABLET	\$.08076
LOVASTATIN	20MG	TABLET	\$.09326
LOVASTATIN	40MG	TABLET	\$.09000
METHOTREXATE	2.5MG	TABLET	\$ 2.17370
METHYLPREDNISOLONE (DOSE PACK)	4MG	TABLET	\$.84329
METRONIDAZOLE	0.75%	VAGINAL GEL	\$.32700
MORPHINE SULFATE	15MG	TABLET CR	\$.56350
MORPHINE SULFATE	30MG	TABLET CR	\$.95060
POTASSIUM CHLORIDE	10MEQ	CAPSULE CR	\$.55060
POTASSIUM CHLORIDE	10MEQ	TABLET CR	\$.33840
QUETIAPINE FUMARATE	25MG	TABLET	\$.11700
QUETIAPINE FUMARATE	50MG	TABLET	\$.17920
QUETIAPINE FUMARATE	100MG	TABLET	\$.20020
QUETIAPINE FUMARATE	200MG	TABLET	\$.35080
QUETIAPINE FUMARATE	300MG	TABLET	\$.48210
QUETIAPINE FUMARATE	400MG	TABLET	\$.48810
TRAZODONE HCL	50MG	TABLET	\$.02994
TRAZODONE HCL	100MG	TABLET	\$.04320
TRAZODONE HCL	150MG	TABLET	\$.09720
TRAZODONE HCL	300MG	TABLET	\$ 3.06580
VALSARTAN-HCTZ	80-12.5MG	TABLET	\$.28880
VALSARTAN-HCTZ	160-12.5MG	TABLET	\$.35860
VALSARTAN-HCTZ	160-25MG	TABLET	\$.34320
VALSARTAN-HCTZ	320-12.5MG	TABLET	\$.37950
VALSARTAN-HCTZ	320-25MG	TABLET	\$.42330

The full SMAC list can be found on the agency's [Pharmacy Information](#) website and applies to claims billed FFS.

Thank you.

AE:AL
 Provider Publications Team
 Medicaid Program
 Health Care Authority

NOTE: Please do not reply directly to this Listserv message as it is not monitored. If you have feedback or questions, select one of the options at <http://hrsa.dshs.wa.gov/contact/default.aspx>. Your message will be delivered to the appropriate staff member.

NOTICE: This message (including any attachments) may contain information that is privileged, confidential, proprietary and/or otherwise protected from disclosure to anyone other than its intended recipient(s). Any dissemination, copying, retention or use of this message or its contents (including any attachments) by persons other than the intended recipient(s) is strictly prohibited. If you have received this message in error, please immediately notify the sender by reply e-mail or telephone and permanently delete all copies of this message and any attachments. Thank you for your cooperation.